AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02499094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral-data driven support
Description: Phone-based support (e.g. triaging of the situation, emotional support, and guidance on next steps for the patient) and in-app support (health education content based on cognitive behavioral therapies, mindfulness, and behavioral activation)
Study NCT02655263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: Somatropin infusion (Genotropin®)
Study NCT02066155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parish nurse
Description: On-going support following diabetes self-management education provided by Parish Nurse
Study NCT02066155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: On-going support following diabetes self-management education provided by a trained person with diabetes
Study NCT03046706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: post operative voice rest
Description: After surgery, a week of total silence. In the second week after surgery talking is allowed for 20 minutes a day.
Study NCT03046706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No voice rest
Description: No limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions
Study NCT03905278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental guidance
Description: A psychological intervention including 4 sessions to assess how participants communicate with their children about the disease and take stock of their questions and difficulties. To identify children's reactions and needs. Practical situation are analyzed and worked through role play centered on communicational difficulties to enhance communicational self-efficacy and mutual support among participants. Emotional regulation strategies are learned through relaxation exercises. A relaxation booklet is given to the participants to practice at home too. Moreover, all participants receive an informational booklet containing age-appropriate recommendations on communication with children about cancer.
Study NCT02251301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skim Milk
Description: 250 ml skim milk will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
Study NCT02251301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training
Description: All participants will undergo a 12 week high intensity interval training program consisting of 3 supervised sessions a week of 4-10 x 1 min high intensity interval alternating with 1 min of recovery.
Study NCT02251301 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: High intensity interval training
Description: All participants will undergo a 12 week high intensity interval training program consisting of 3 supervised sessions a week of 4-10 x 1 min high intensity interval alternating with 1 min of recovery.
Study NCT02251301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: All participants will undergo a 12 week high intensity interval training program consisting of 3 supervised sessions a week of 4-10 x 1 min high intensity interval alternating with 1 min of recovery.
Study NCT02655263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketone bodies
Description: ketone bodies infusion
Study NCT01478230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine 5 mg Inhaler
Study NCT01478230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Nicotine 10 mg Inhaler
Study NCT03397888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: 80 mg capsule
Study NCT03663127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beauty Drink
Description: Subjects receive two bottles of Beauty Drink per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
Study NCT03663127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive two bottles of placebo of similar appearance per day for 8 weeks of a stage. In addition, anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
Study NCT03836430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Newborn Behavioral Observation-Family Wellness (NBO-FW)
Description: The intervention has been described in the arm description.
Study NCT01904149 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo single oral dose (first 8 hours)
Study NCT01904149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen-single dose
Description: Dexketoprofen single oral dose (first 8 hours)
Study NCT01904149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol-single dose
Description: Tramadol single oral dose (first 8 hours)
Study NCT01904149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen/Tramadol-single dose
Description: Dexketoprofen/Tramadol single oral dose (first 8 hours)
Study NCT01904149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen-multiple doses
Description: Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)
Study NCT01904149 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexketoprofen-multiple doses
Description: Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)
Study NCT01904149 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tramadol-multiple doses
Description: Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
Study NCT01904149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol-multiple doses
Description: Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
Study NCT01904149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen/Tramadol-multiple doses
Description: Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
Study NCT01904149 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexketoprofen/Tramadol-multiple doses
Description: Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
Study NCT00838825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: introduction of the chronic care model
Description: The care management team is organized according to the chronic care model for health care delivery. They are supported by an information registry for diabetes, receive instruction in self-management, have redesigned their work flow to include delegation of functions to care managers who follow specific guidelines and protocols for managing diabetes
Study NCT01641146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Sexual Health Intervention for Men (ES-HIM)
Description: ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
Study NCT01641146 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion (HP) Comparison Arm
Description: Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
Study NCT04326725 — intervention group
Intervention type: DRUG
Intervention: Plaquenil 200Mg Tablet
Description: health workers under risk who took this medications
Study NCT02227173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986020
Study NCT02227173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Study NCT02227173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Study NCT02227173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study NCT01452230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised physical activity
Description: Supervised physical activity
Study NCT03404804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Oral challenge with amoxicillin in patients who are deemed low-risk for true penicillin allergy
Study NCT04350671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Beta-1A
Description: This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Interferon-β 1a in COVID-19 patients.
Study NCT04350671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir / Ritonavir
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study NCT04350671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study NCT04350671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose of Hydroxychloroquine
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study NCT04350671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Dose of Hydroxychloroquine
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study NCT00711347 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DisCoVisc
Description: Use of Alcon's DisCoVisc Ophthalmic Viscosurgical Device(4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery with intraocular lens implantation.
Study NCT00711347 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Healon5
Description: Use of Abbott Medical Optics (AMO) Healon5 Ophthalmic Viscosurgical Device (2.3% Sodium Hyaluronate) during cataract surgery with intraocular lens implantation.
Study NCT00823992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sc once weekly
Study NCT00823992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg sc once weekly for 4 weeks, then 20mg sc once weekly
Study NCT02636244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE Gel
Study NCT01655043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Regadenoson will be infused intravenously 0.4 mg/5 mL (0.08 mg/mL) as a single bolus.
Study NCT01655043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadofoveset trisodium
Description: All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar) at both stress and rest.
Study NCT02251301 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mL water will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
Study NCT02251301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Macronutrient isoenergetic control
Description: 250 mL of protein+cho matched drink will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
Study NCT03765658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT0151Y dose escalation
Description: Single doses of 150, 200, 250, 300, 350 and 400 mg (3, 4, 5, 6, 7 or 8 capsules of 50 mg)
Study NCT03765658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo capsules (3, 4, 5, 6, 7 or 8 capsules)
Study NCT01825720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Glucose-Insulin-Potassium)GIK group
Description: infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
Study NCT01825720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline group
Description: same rate of normal saline
Study NCT03385759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unicompartmental knee arthroplasty
Description: Implant to replace the medial compartment of a patient with knee osteoarthritis
Study NCT03385759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Implant to replace the knee joint of a patient with knee osteoarthritis
Study NCT02399241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bluetooth enabled nebuliser device (I-neb)
Study NCT00570999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 60 mg/kg/day
Study NCT02229214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qsymia
Study NCT00570999 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1,2 mL once daily
Study NCT03224806 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wholegrain bread
Description: 156.8g wholegrain bread
Study NCT03224806 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: White bread
Description: 122.6g white bread
Study NCT03224806 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 15% fiber-rich bread
Description: 139.2g bread made with 15% added wheat bran
Study NCT03224806 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 30% fiber-rich bread
Description: 166.5g bread made with 30% added wheat bran
Study NCT02229214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01080768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine
Description: Aliskiren/amlodipine 150/5 mg/day
Study NCT01080768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5 mg/day.
Study NCT01080768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Aliskiren/amlodipine
Description: Placebo to Aliskiren/amlodipine 150/10 mg/day
Study NCT01080768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Amlodipine
Description: Placebo to Amlodipine 5 mg/day
Study NCT00975104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 745 0.3 mg/kg
Description: AMG 745 0.3 mg/kg IV QW
Study NCT00975104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 745 1.0 mg/kg
Description: AMG 745 1.0 mg/kg IV QW
Study NCT00975104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 745 3.0 mg/kg
Description: AMG 745 3.0 mg/kg IV QW
Study NCT00975104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV QW
Study NCT02386098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: HIV Maturation Inhibitor
Study NCT02386098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV)
Description: Atazanavir
Study NCT02386098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir (ATV)
Description: Atazanavir
Study NCT02386098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Description: Ritonavir
Study NCT02386098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir (RTV)
Description: Ritonavir
Study NCT02386098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: Dolutegravir
Study NCT02386098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dolutegravir (DTG)
Description: Dolutegravir
Study NCT02386098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir (TDF)
Description: Tenofovir
Study NCT04037020 — intervention group
Intervention type: OTHER
Intervention: Chocolate
Description: Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (extreme dark (90%), dark (70%), milk (38%), and white (0%)).
Study NCT01331772 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control arm
Description: Dietetic follow-up only
Study NCT01331772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention arm
Description: Dietetic follow up + adapted physical activity
Study NCT04555668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation Program
Description: Global Postural Reeducation Program with hamstring stretch The lying posture with flexion of the legs aimed to stretch the posterior chain (upper trapezius, levator scapulae, sub occipital, erector spinae, gluteus maximus, ischio-tibial, triceps surae, and foot intrinsic muscles). The initial position will lying with the hip flexed and progression consisted of increasing hip flexion, knee extension, and dorsiflexion of the ankle All above exercises will be given and to be held for 15 minutes each. 40 min/session, 3 times/week for 6 weeks
Study NCT04555668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hamstring Stretch Program
Description: Hamstring Stretch Program 3 times for 30 seconds hold, subjects rested for 15 seconds between stretches. Knee -flexor eccentric training to prevent hamstring muscle strain 10-15 rep 40 min/session, 3 times/week for 6 weeks
Study NCT01920126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate
Description: 0.5 mmol/kg for 1 hr, and then 0.15 mmol/kg/h for 23 hrs The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
Study NCT01920126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT00509756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FXR-450
Description: capsule, single oral doses from 10 mg to 450 mg
Study NCT01252550 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Activia® (125g/pot)
Description: Activia® (125g/pot) - dairy product containing bacterial culture Acti Regularis®
Study NCT00509756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule similar to active drug
Study NCT04703907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular stimulation
Description: Auricular acupuncture-like stimulation (percutaneous sensory stimulation of cranial nerves)
Study NCT03865004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol+Morphine
Description: 1gr paracetamol plus 0.1 mg/kg morphine were performed simultanously
Study NCT03865004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol+Morphine
Description: 1gr paracetamol plus 0.1 mg/kg morphine were performed simultanously
Study NCT03865004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen plus Morphine
Description: Intravenous 75 mg Dexketoprofen plus 0,1 mg/kg morphine were performed simultanously
Study NCT03865004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexketoprofen plus Morphine
Description: Intravenous 75 mg Dexketoprofen plus 0,1 mg/kg morphine were performed simultanously
Study NCT03865004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus Morphine
Description: 100 cc NaCl plus 0.1 mg/kg morphine were performed simultanously
Study NCT03865004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Morphine
Description: 100 cc NaCl plus 0.1 mg/kg morphine were performed simultanously